https://www.selleckchem.com/products/dmh1.html
To describe the safety and efficacy of opicapone, a newly Food and Drug Administration-approved catechol- -methyltransferase (COMT) inhibitor, as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing episodes. A literature search through PubMed and International Pharmaceutical Abstracts (January 2000 to October 202 was conducted using the following search terms , and . Articles selected included those describing preclinical and clinical studies examining the pharmacokinetics, efficacy, and/o
Like
Comment
Share
